how does glp-1 delay gastric emptying Gastrointestinal Motility Effects of Receptor Agonists | Current Gastroenterology Reports a) GLP-1R mediated decrease in

Recently, 15 mg tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, reduced the body weight of patients with obesity by 20.9% from baseline compared with placebo in the SURMOUNT-1 trial [15]

The rising prevalence of type 2 diabetes and obesity, increasing adoption for chronic weight management among non-diabetic populations, expansion of pharmaceutical R&D pipelines, and growing demand in emerging markets with high metabolic disease burden are key drivers of market growth

Comprehensive blood testing with Ulta Lab Tests can be a valuable resource in this process

5,6 Increasing physical activity is also recommended as it has been shown to improve glycemic control